Pharsight

1. Acanya patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561208	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US10220049	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US9504704	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US8895070	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US10137142	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US10624918	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US8663699	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US9078870	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US8288434	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Aug, 2029 (5 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 23 October, 2008

Treatment: Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne vulgaris; Topical treatment of acne vulgaris; Treatment of acne

Dosage: GEL;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1.2%/2.5%	20 Dec, 2012	1	19 Jun, 2015	05 Aug, 2029	Eligible
1.2%/3.75%	30 Sep, 2015	1	05 Jun, 2018	05 Aug, 2029	Eligible

Strength	Dosage	Availability
2.5%;EQ 1.2% BASE	GEL;TOPICAL	Prescription
3.75%;EQ 1.2% BASE	GEL;TOPICAL	Prescription

ACANYA family patents

2. Aldara patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696159	BAUSCH	Treatment for basal cell carcinoma	Apr, 2024 (4 months from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159 (Pediatric)	BAUSCH	Treatment for basal cell carcinoma	Oct, 2024 (10 months from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.05	17 Oct, 2006	1	25 Feb, 2010	24 Aug, 2010	Eligible

Strength	Dosage	Availability
5%	CREAM;TOPICAL	Prescription

ALDARA family patents

3. Aplenzin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7585897	BAUSCH	Modified release formulations of a bupropion salt	Jun, 2026 (2 years from now)
US7572935	BAUSCH	Modified release formulations of a bupropion salt	Jun, 2026 (2 years from now)
US7241805	BAUSCH	Modified release formulations of a bupropion salt	Jun, 2026 (2 years from now)
US7649019	BAUSCH	Modified release formulations of a bupropion salt	Jun, 2026 (2 years from now)
US7671094	BAUSCH	Bupropion hydrobromide and therapeutic applications	Jun, 2026 (2 years from now)
US7645802	BAUSCH	Bupropion hydrobromide and therapeutic applications	Jun, 2026 (2 years from now)
US7662407	BAUSCH	Modified release formulations of a bupropion salt	Jun, 2026 (2 years from now)
US7569610	BAUSCH	Modified release formulations of a bupropion salt	Jun, 2026 (2 years from now)

Drugs and Companies using BUPROPION HYDROBROMIDE ingredient

Market Authorisation Date: 23 April, 2008

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
174 mg	28 Sep, 2009	1	27 Jun, 2026	Extinguished
348 mg	24 Sep, 2009	1	27 Jun, 2026	Extinguished
522 mg	24 Dec, 2009	1	27 Jun, 2026	Extinguished

Strength	Dosage	Availability
174MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
348MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
522MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

APLENZIN family patents

4. Arazlo patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11311482	June, 2023	Notice of Filing Date Accorded	Bausch Health Ireland Limited et al.	Padagis Israel Pharmaceuticals Ltd. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679116	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US11311482	BAUSCH	Topical compositions and methods for treating skin diseases	May, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Dec 18, 2022

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 18 December, 2019

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00045	12 May, 2022	1		11 May, 2038

Strength	Dosage	Availability
0.045%	LOTION;TOPICAL	Prescription

ARAZLO family patents

5. Bryhali patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809307	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US10478502	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2018

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0001	15 May, 2019	1		02 Nov, 2031

Strength	Dosage	Availability
0.01%	LOTION;TOPICAL	Prescription

BRYHALI family patents

6. Cabtreo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624918	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US10220049	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US9561208	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (5 years from now)
US8288434	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Aug, 2029 (5 years from now)
US11389467	BAUSCH	Topical compositions	Dec, 2040 (17 years from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2023

Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.15%;3.1%;1.2%	GEL;TOPICAL	Prescription

CABTREO family patents

7. Duobrii patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US8809307	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US11648256	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US10251895	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US10426787	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US11679115	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.01%/0.045%	11 Jun, 2020	1		06 Jun, 2036

Strength	Dosage	Availability
0.01%;0.045%	LOTION;TOPICAL	Prescription

DUOBRII family patents

8. Jublia patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7214506	May, 2017	FWD Entered	Kaken Pharmaceutical Co., Ltd.	Argentum Pharmaceuticals LLC
US7214506	November, 2016	FWD Entered	Kaken Pharmaceutical Co., Ltd.	Acrux DDS Pty Ltd.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214506	BAUSCH	Method for treating onychomycosis	Feb, 2026 (2 years from now)
US11213519	BAUSCH	Compositions and methods for treating diseases of the nail	Jan, 2028 (4 years from now)
US10512640	BAUSCH	Compositions and methods for treating diseases of the nail	Jan, 2028 (4 years from now)
US9566272	BAUSCH	Compositions and methods for treating diseases of the nail	Jan, 2028 (4 years from now)
US10828369	BAUSCH	Compositions and methods for treating diseases of the nail	Jan, 2028 (4 years from now)
US9877955	BAUSCH	Compositions and methods for treating diseases of the nail	Jan, 2028 (4 years from now)
US8039494	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (6 years from now)
US10105444	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (6 years from now)
US9861698	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (6 years from now)
US8486978	BAUSCH	Compositions and methods for treating diseases of the nail	Oct, 2030 (6 years from now)
US9302009	BAUSCH	Compositions and methods for treating diseases of the nail	Oct, 2030 (6 years from now)
US10864274	BAUSCH	Stabilized efinaconazole formulations	Oct, 2034 (10 years from now)
US10828293	BAUSCH	Anti-infective methods, compositions, and devices	Oct, 2034 (10 years from now)
US10342875	BAUSCH	Stabilized efinaconazole compositions	Oct, 2034 (10 years from now)
US9662394	BAUSCH	Stabilized efinaconazole compositions	Oct, 2034 (10 years from now)
US11654139	BAUSCH	Anti-infective methods, compositions, and devices	Oct, 2034 (10 years from now)
US10478601	BAUSCH	Applicator	Apr, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of onychomycosis of the toe...

Dosage: SOLUTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.1	06 Jun, 2018	19	16 Dec, 2020	02 Oct, 2034	Eligible

Strength	Dosage	Availability
10%	SOLUTION;TOPICAL	Prescription

JUBLIA family patents

9. Locoid patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7981877	BAUSCH	Stabilized steroid composition and method for its preparation	Jan, 2025 (1 year, 1 month from now)
US7378405	BAUSCH	Stabilized steroid composition and method for its preparation	Dec, 2026 (3 years from now)

Drugs and Companies using HYDROCORTISONE BUTYRATE ingredient

Market Authorisation Date: 18 May, 2007

Treatment: NA

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.001	31 Aug, 2016	1	21 Nov, 2017	19 Dec, 2026	Eligible

Strength	Dosage	Availability
0.1%	LOTION;TOPICAL	Prescription

LOCOID family patents

10. Luzu patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9199977	BAUSCH	Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal	Sep, 2033 (9 years from now)
US9012484	BAUSCH	Crystal and pharmaceutical preparation containing the same crystal	Sep, 2033 (9 years from now)
US9453006	BAUSCH	Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient	Sep, 2033 (9 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931	BAUSCH	Method of evaluating pharmaceutical preparation containing luliconazole and index substance	Apr, 2034 (10 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Market Authorisation Date: 14 November, 2013

Treatment: Treatment of fungal infections

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
1%	CREAM;TOPICAL	Prescription

LUZU family patents

11. Solodyn patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268804	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 6 months from now)
US7790705	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 6 months from now)
US8252776	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 6 months from now)
US8722650	BAUSCH	Extended-release minocycline dosage forms	Jun, 2025 (1 year, 6 months from now)
US7919483	BAUSCH	Method for the treatment of acne	Mar, 2027 (3 years from now)
US7544373	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (3 years from now)
US7541347	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (3 years from now)
US9192615	BAUSCH	Method for the treatment of acne and certain dosage forms thereof	Nov, 2031 (7 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2006

Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
45 mg, 90 mg and 135 mg
55 mg	02 Dec, 2010	1	30 Nov, 2011	20 Nov, 2025	Eligible
65 mg and 115 mg	19 Nov, 2009	1	18 May, 2012	19 Feb, 2018	Extinguished Eligible
80 mg	27 Oct, 2010	1	25 Sep, 2014	19 Feb, 2018	Non-Forfeiture
105 mg	13 Dec, 2010	1		19 Feb, 2018	Non-Forfeiture

Strength	Dosage	Availability
EQ 45MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 55MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 65MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 80MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 90MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 105MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 115MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 135MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

SOLODYN family patents

12. Vanos patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7794738	BAUSCH	Compositions and methods for enhancing corticosteroid delivery	Sep, 2022 (1 year, 2 months ago)
US7220424	BAUSCH	Compositions and methods for enhancing corticosteroid delivery	Jan, 2023 (10 months ago)
US8232264	BAUSCH	Compositions and methods for enhancing corticosteroid delivery	Mar, 2023 (8 months ago)

Drugs and Companies using FLUOCINONIDE ingredient

Market Authorisation Date: 11 February, 2005

Treatment: Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.001	31 Jan, 2008	1	14 Jan, 2014	21 Dec, 2021	Eligible

Strength	Dosage	Availability
0.1%	CREAM;TOPICAL	Prescription

VANOS family patents

13. Xerese patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223387	BAUSCH	Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester	Nov, 2022 (1 year, 17 days ago)

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolesc...

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
5%;1%	CREAM;TOPICAL	Prescription

XERESE family patents

14. Zyclara patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238645	BAUSCH	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Aug, 2029 (5 years from now)
US8598196	BAUSCH	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	Aug, 2029 (5 years from now)
US10238644	BAUSCH	2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec, 2029 (6 years from now)
US11318130	BAUSCH	2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec, 2029 (6 years from now)
US8236816	BAUSCH	2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod	Dec, 2029 (6 years from now)
US8222270	BAUSCH	2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod	Dec, 2029 (6 years from now)
US8299109	BAUSCH	Method of treating actinic keratosis with 3.75% imiquimod cream	Dec, 2029 (6 years from now)
US10918635	BAUSCH	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Apr, 2030 (6 years from now)
US11202752	BAUSCH	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	Apr, 2030 (6 years from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 25 March, 2010

Treatment: Treatment of genital warts; Treatment of perianal warts; Treatment of actinic keratosis

Dosage: CREAM;TOPICAL

Pharsight

Bausch patents expiration

1. Acanya patents expiration

ACANYA family patents

2. Aldara patents expiration

ALDARA family patents

3. Aplenzin patents expiration

APLENZIN family patents

4. Arazlo patents expiration

ARAZLO family patents

5. Bryhali patents expiration

BRYHALI family patents

6. Cabtreo patents expiration

CABTREO family patents

7. Duobrii patents expiration

DUOBRII family patents

8. Jublia patents expiration

JUBLIA family patents

9. Locoid patents expiration

LOCOID family patents

10. Luzu patents expiration

LUZU family patents

11. Solodyn patents expiration

SOLODYN family patents

12. Vanos patents expiration

VANOS family patents

13. Xerese patents expiration

XERESE family patents

14. Zyclara patents expiration

ZYCLARA family patents

Related content

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.025	17 Jun, 2014	1		11 Dec, 2029
0.0375	08 Aug, 2012	1		11 Dec, 2029	Non-Forfeiture

Pharsight

Bausch patents expiration

1. Acanya patents expiration Share with your colleague

ACANYA family patents

2. Aldara patents expiration Share with your colleague

ALDARA family patents

3. Aplenzin patents expiration Share with your colleague

APLENZIN family patents

4. Arazlo patents expiration Share with your colleague

ARAZLO family patents

5. Bryhali patents expiration Share with your colleague

BRYHALI family patents

6. Cabtreo patents expiration Share with your colleague

CABTREO family patents

7. Duobrii patents expiration Share with your colleague

DUOBRII family patents

8. Jublia patents expiration Share with your colleague

JUBLIA family patents

9. Locoid patents expiration Share with your colleague

LOCOID family patents

10. Luzu patents expiration Share with your colleague

LUZU family patents

11. Solodyn patents expiration Share with your colleague

SOLODYN family patents

12. Vanos patents expiration Share with your colleague

VANOS family patents

13. Xerese patents expiration Share with your colleague

XERESE family patents

14. Zyclara patents expiration Share with your colleague

ZYCLARA family patents

Related content

1. Acanya patents expiration

2. Aldara patents expiration

3. Aplenzin patents expiration

4. Arazlo patents expiration

5. Bryhali patents expiration

6. Cabtreo patents expiration

7. Duobrii patents expiration

8. Jublia patents expiration

9. Locoid patents expiration

10. Luzu patents expiration

11. Solodyn patents expiration

12. Vanos patents expiration

13. Xerese patents expiration

14. Zyclara patents expiration